Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon and NIH CRM Collaborate to Apply rAAV Genome Editing to Stem Cells

Published: Friday, October 05, 2012
Last Updated: Friday, October 05, 2012
Bookmark and Share
Collaboration aims to understand the effects of specific gene sequences on stem cell differentiation.

Horizon Discovery (Horizon) has announced that it has signed a technology access agreement with the U.S. National Institutes of Health Center for Regenerative Medicine (NIH CRM), through Horizon’s Centers of Excellence (CoE) program.

The agreement will enable the NIH CRM to apply Horizon’s GENESIS™ genome editing technology to engineer stem cells in order to create isogenic disease models with induced mutations and/or lineage markers.

These disease models will be used to help researchers understand the effects of specific genes and mutations as stem cells differentiate, as well as create lineage reporters for stem cell differentiation.

The NIH CRM was recently established through support from the NIH Common Fund to provide the infrastructure to support and accelerate the clinical translation of stem cell-based technologies, and to develop widely available resources to be used as standards in stem cell research.

The GENESIS technology harnesses rAAV vectors to perform accurate and efficient gene-editing functions in human cells, by switching on a natural high-fidelity DNA-repair mechanism called homologous recombination (HR).

When harnessed using rAAV gene-editing vectors, HR allows the precise alteration of any DNA sequence, permitting the accurate modeling of genetic diseases in human cells, including stem cells, in vitro.

The use of these models in oncology is well established, and has predicted patient responses to targeted therapies both during drug development and in the clinic.

By applying this technology to other scientific areas Horizon hopes to lead to the development of personalized medicines by advancing scientific research.

“Through our CoE program, we aim to work with world leading experts in their fields, so we are delighted to be working with the NIH CRM, a key centre for stem cell research,” said Dr Rob Howes, CoE Program Manager, Horizon Discovery.

Dr Howes continued, “This agreement builds on proof of concept work carried out by Horizon Scientific Advisory Board member and rAAV-mediated gene editing inventor, David Russell, demonstrating the ability of rAAV to gene target in ES cells, and extends the scope of the CoE program into stem cell research.”

Horizon’s CoE program encompasses academic and not-for-profit research groups or laboratories to which Horizon commits resources to provide training and open access to its proprietary rAAV-mediated human gene-editing platform, GENESIS™.

Horizon also recently launched an online support site, www.rAAVers.org, for scientists working with rAAV-mediated genome editing.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon Establishes Three New CoE in rAAV-mediated Cellular Genome Editing
Dana-Farber Cancer Institute, University of Liverpool, and Babraham Institute join CoE network.
Tuesday, June 26, 2012
Horizon Joins 4D Cell Fate Consortium
Contributes rAAV-mediated genome editing technology to EU FP7 funded project aimed at understanding hES cell differentiation control.
Tuesday, June 05, 2012
Collaboration to Apply rAAV Gene Targeting in Mouse Embryonic Stem Cells and Research into EGFR-Therapy Resistance
Horizon Discovery announces that it has entered into a three-year collaboration with the Fox Chase Cancer Center.
Tuesday, April 19, 2011
Horizon and UW Announce Collaboration to Apply rAAV Gene Editing in Inducible Human Pluripotent Stem Cells
Collaboration aims to widen the utilization of Horizon’s rAAV-GENESIS platform technology X-MAN™ in creating genetically-defined human cell lines.
Monday, January 10, 2011
Horizon Discovery Sign Worldwide Exclusive License to new Inventions from University of Torino
License relates to the use of human isogenic cell-lines in predicting the response of drugs targeted at the genetic make-up of individual cancer patients.
Tuesday, August 11, 2009
GeneWorks Forms Commercial Alliance with Horizon Discovery
GeneWorks to offer translational genomics capabilities to researchers in Australia and New Zealand.
Thursday, January 08, 2009
The X-MAN Steps-Out: Horizon Discovery Sign Screening and License Agreements with Agios Pharmaceuticals
Horizon Discovery (Horizon) today announced it has signed two commercial agreements with a ground-breaking U.S. cancer start-up; Agios Pharmaceuticals (Agios), relating to its X-MAN technology.
Wednesday, October 01, 2008
Scientific News
The Mending Tissue - Cellular Instructions for Tissue Repair
NUS-led collaborative study identifies universal mechanism that explains how tissue shape regulates physiological processes such as wound healing and embryo development.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
iPS Cells Discover Drug Target for Muscle Disease
Researchers have designed a model that reprograms fibroblasts to the early stages of their differentiation into intact muscle cells in a step towards a therapeutic for Duchenne muscular dystrophy.
Engineered Hot Fat Implants Reduce Weight Gain
Scientists at UC Berkeley have developed a novel way to engineer the growth and expansion of energy-burning “good” fat, and then found that this fat helped reduce weight gain and lower blood glucose levels in mice.
Transplanted Stem Cells Can Benefit Retinal Disease Sufferers
Tests on animal models show that MSCs secrete growth factors that suppress causes of diabetic retinopathy and macular degeneration.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
Team Finds Early Inflammatory Response Paralyzes T Cells
Findings could have enormous implications for immunotherapy, autoimmune disorders, transplants and other aspects of immunity.
Early Detection of Lung Cancer
The University of Manchester has signed a collaboration agreement with Abcodia to perform proteomics studies on a cohort of non-small cell lung cancer cases from the UKCTOCS biobank, with the aim of discovering new blood-based biomarkers for earlier detection of the disease.
Researchers Identify Drug Candidate for Skin, Hair Regeneration
Formerly undiscovered role of protein may lead to the development of new medications that stimulate hair and skin regeneration in trauma or burn victims.
Basis for New Treatment Options for a Fatal Leukemia in Children Revealed
Detailed molecular analyses allow new insights into the function of tumour cells and options for new treatments.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!